Is Zom a good stock to buy?
· Zomedica's stock was trading at $0.2078 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM shares have increased by 15.5% and is now trading at $0.24. View which stocks have been most impacted by COVID-19.
Will Zom price go up or down in 14 days?
Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues. ZOM is looking GOOD!, loaded up in low 0.20's ...
Can zomedica stock reach three dollars?
· As people who invest in stocks will know, this tends to increase hype and awareness, raising the stock price. However, the current price of ZOM is sitting around 81% lower than the peak of $2.71 that was reached back in March 2021.
What is the price of Zom in US dollars?
· Zom stock has traded in a 52-week range with $2.91 as the ceiling and $0.24 as the floor. It is presently trading at $0.31 as of writing, closer to its 52-week bottom. The current price is testing the support formed by the Q4 2019 price at 0.3048, which has so far held firm.
How has Zomedica's stock been impacted by COVID-19 (Coronavirus)?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per shar...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 14th. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Robert Cohen , CEO & Director (Age 63, Pay $412.79k) Ms. Ann Marie Cotter CPA , C...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Protagonist Therapeutics (PTGX) , Keros Therapeutics (KROS) , Myovant Sciences (MYOV) , Axs...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (2.93%), BlackR...
Which institutional investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Commonwealt...
What is ZOM?
Zomedica Pharmaceuticals is a veterinary health company that produces point-of-care diagnostic devices for veterinarians. Zomedica has just begun s...
Is ZOM a good investment opportunity?
As a small-cap stock, ZOM is an excellent investment if you are looking for huge gains. However, as you can imagine, small-cap stocks are much risk...
Where can I buy ZOM stock?
We recommend using eToro if you are looking to buy Zomedica stock. eToro offers 0% commission trading and fractional investing, making the platform...
Will the price of ZOM go up in the future?
If Zomedica can begin showing some solid revenue growth, it’s highly likely that the stock will increase. Although it may be more of a long-term pl...
Is buying ZOM risky?
As noted, due to ZOM being a small-cap stock, it is much riskier than buying an established stock. However, this provides the opportunity for more...
How do hedge funds control the price?
Is Zomedica a good stock?
very common strategy to be used by hedge funds to control the price. simply buy and hold, this price is a discount. good luck.
Is a zom part of an index?
Zomedica being added to MSCI proves it's seen as a growth stock, potentially even having dividends in the future. This addition can potentially increase trading and volume. The MSCI indexes are similar to the Dow Jones Averages or the S&P 500. This is very good news.
How much is Zomedica stock worth in 2021?
Remember ZOM is part of an index. Institutions buy the underlying symbols in the index. Hence a vast majority of institutions hold ZOM.
Is Zomedica Pharmaceuticals Corp a negative stock?
The Zomedica Pharmaceuticals Corp stock price gained 3.73% on the last trading day (Friday, 9th Jul 2021), rising from $0.71 to $0.74. During the day the stock fluctuated 4.11% from a day low at $0.72 to a day high of $0.75. The price has fallen in 6 of the last 10 days and is down by -12.33% for this period. Volume fell on the last day by -6 million shares and in total, 18 million shares were bought and sold for approximately $13.09 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Which is the best platform to buy ZOM?
Zomedica Pharmaceuticals Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
How to trade Zomedica?
However, through our research and testing, we’ve noted that eToro offers the best platform to buy ZOM shares today. This is because you can invest in stocks with 0% commission when using eToro and from as little as $50. So, with that in mind, here are the four steps you need to follow to buy ZOM right now.
How much does eToro take?
When you are ready, click into the search bar at the top of the screen and type in ‘ZOM’, which is Zomedica’s ticker symbol. Click ‘Trade’ next to the first option, and an order box should now appear. In this box, enter your desired position size, double-check everything is correct, and click ‘Open Trade’.
What is Zomedica Pharmaceuticals?
eToro accepts deposits from as little as $50, with deposits entirely free to make. In terms of methods, eToro accepts funding from the following:
How fast is the veterinary diagnostics industry growing?
Zomedica Pharmaceuticals is a veterinary health company that produces point-of-care diagnostic devices for veterinarians. Zomedica has just begun selling their TRUFORM device in March 2021, so revenues have only started rolling in within the past seven months.
What is Zomedica Corp?
Huge Industry: The veterinary diagnostics field is expected to grow at a rate of 10% per year between now and 2026, according to data gathered from Fortune Business Insights. As such, Zomedica is growing at precisely the right time to make the most of this market opportunity.
What is Zomedica's business model?
Zomedica Corp. (ZOM) is a veterinary health company based in Ann Arbor that develops and markets point-of-care diagnostics. These products and services refer to the process of identifying medical issues in companion animals in real-time, which is much faster than the current process allows, meaning animals can be treated more efficiently. This looks to be a lucrative market for ZOM, as the amount of people with companion animals has skyrocketed since the COVID-19 pandemic.
How many Zom stocks were shorted on June 3?
One exciting aspect of Zomedica’s business model is that the company has changed to a ‘direct to consumer’ approach. This cuts out the distributor, meaning that Zomedica can really begin ramping up its marketing and increase hype about the product. Ultimately, once more devices are added to Zomedica’s portfolio, this direct selling method will offer them more control over pricing, meaning larger revenues in the future.
How much cash does Zomedica have in 2021?
According to data from Fintel, over 50 million shares of ZOM stock were sold short on June 3, which was 35 percent of the trading volume on that day. Along with the short squeeze, the rally in meme stocks seems to be driving ZOM stock higher.
Will Zom stock rise in 2021?
Zomedica went overboard with stock issuance and as a result, it had cash and cash equivalents of $276.6 million as of March 31, 2021. The stock issuance was done at a higher price than what ZOM currently trades at.
Is Zom a pre-revenue company?
ZOM stock could rise more from these levels. The rise in the stock hasn’t been speculative like it was in the first quarter of 2021. The stock has been going up as the company advances to scale up its capabilities to commercialize Truforma. Overall, I expect the rally in ZOM stock to continue.
Is Zom stock bullish?
While the revenues aren't much, it signals that ZOM isn't a pre-revenue company. If the Truforma product can gain traction in the market, better days could lie ahead for Zomedica stock. The market for pet care is growing fast, which bodes well for Zomedica.
Zom Stock News
ZOM stock has crossed above its 50-day SMA (simple moving average), which is a bullish indicator. On the downside, the 200-day SMA has been strong support for the stock.
Will Zom Stock Go Up?
The earnings report of 25 February 2022 will constitute a ZOM stock news of interest. The only significant news of note after the retirement of erstwhile CEO Robert Cohen back in October 2021 was the recent press conference by the new CEO, which provided an update on the progress of new diagnostic assay developments.
Zom Stock Forecast 2022
Zomedica’s share price has been in a slump for the major part of 2021.
Zom Stock Forecast 2025
What is the Zom stock forecast for 2022? The Zom stock forecast 2022 is a medium-term forecast that aims to predict the Zom stock price in the next few months. Following the completion of the double top on the weekly chart, price action is now trading around the measured move’s completion zone.
ZOM: Monthly Chart
The Zom stock forecast 2025 retains the bearish outlook that has permeated the stock for the latter part of 2021. There aren’t positive fundamentals to suggest a change in sentiment. Any rallies would be purely speculative and would only provide opportunities for traders looking to make huge gains by shorting the stock.
Zom Stock forecast 2030
The monthly chart shows that the RSI still has room to head into the oversold region, while there is a lack of good buying volume. Indeed, trading volumes are fragile. The current support at 0.3048 remains the only factor holding price activity from declining further.
Is Zom a Good Stock to Buy
If you have a long term view and want to get some insight via the Zom stock forecast 2025, then this is where it gets interesting. CEO Larry Heaton recently delivered an address where he outlined the company’s strategy for driving sales of Truforma. This is to be based on three pillars:
How many sales reps does Zomedica have in 2021?
ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.
Is the sales force getting into the field?
Then there’s the question of the sales force. By the end of 2021, Zomedica says the sales group will have 15 reps. They will be supported by four professional services veterinarians and support employees. That’s at the end of 2021.
Is Zomedica going to the moon?
That may be correct. The sales force is only now getting into the field. Tests that give the platform value are still in the pipeline. That value may be enormous, assuming the tests can be made.
ZOM Stock: Upcoming Catalysts Do Not Justify Its Strong Performance
Zomedica ( NYSEAMERICAN: ZOM) stock was said to be going “to the moon” on Reddit early this year. ZOM did zoom, to as high as $2.50 per share, twice.
Why It Could Be Déjà Vu All Over Again
Zomedica shares were already up substantially before the recent move from $1 to $2 per share. Now up more than thirty-fold, why do shares keep on climbing? It’s simple. Those who didn’t buy in early are kicking themselves.
Bottom Line: Be Careful, Even if Shares Pull Back
In January, many heavily shorted stocks headed to the moon. But, as February plays out, many of these are heading back down to earth. However, while the short-squeeze trade is fading, this name could see some benefit from a retail investor-fueled squeeze.
A Closer Look at ZOM Stock
Zomedica may be too risky at today’s $2.50 per share. But, is ZOM stock a worthwhile opportunity if it pulls back to near $1 per share? Not so fast. For sure, the company is worth more now than it was just a few months ago. The commercialization of Truforma and other products will likely result in improved results for its top and bottom line.
First, the Bad News
A year ago, the situation of Zomedica’s investors was much better than it is today. Amazingly, ZOM stock shot up from 10 cents in late 2020 to a 52-week high of $2.91 on Feb. 8, 2021.
A Shocking Discovery
Now I’m not going to sugarcoat the value proposition of Zomedica. It’s a small company with lackluster financials, to put it politely.
The Bottom Line
What was this acquisition? That is the billion-dollar question for Zomedica’s stakeholders.